复发或难治性高级别髓系肿瘤的早期异基因造血细胞移植治疗
该数据集来自 clinicaltrials.gov,聚焦复发或难治性高级别髓系肿瘤患者接受早期异基因造血细胞移植的治疗方案

基本信息
资源简介
复发或难治性高级别髓系肿瘤的早期异基因造血细胞移植治疗
该数据集来自 clinicaltrials.gov,聚焦复发或难治性高级别髓系肿瘤患者接受早期异基因造血细胞移植的治疗方案。覆盖骨髓原始细胞≥10%、慢性粒单核细胞白血病-2、高级别恶性肿瘤、骨髓增生异常综合征、伴原始细胞过多-2的骨髓增生异常综合征、髓系肿瘤及既往治疗过的骨髓增生异常综合征、复发性急性髓系白血病等病种。数据可用于研究再诱导化疗与预处理方案(含非格司亭、米托蒽醌、克拉屈滨、阿糖胞苷、氟达拉滨、美法仑、环孢素、西罗莫司等)在移植治疗中的效果与预后预测(来源 clinicaltrials.gov)。
【数据内容】
源站描述(机器翻译,仅供参考):条件:骨髓有核细胞中原始细胞占10%或以上,慢性粒单核细胞白血病-2,高级别恶性肿瘤,骨髓增生异常综合征,伴原始细胞过多-2的骨髓增生异常综合征,髓系肿瘤,既往治疗过的骨髓增生异常综合征,复发性急性髓系白血病。方案概要:再诱导化疗:患者在第0-5天皮下注射非格司亭,第1-3天静脉输注盐酸米托蒽醌60分钟,第1-5天静脉输注克拉屈滨2小时,第1-5天静脉输注阿糖胞苷2小时。预处理方案:再诱导化疗开始后14-60天,患者在第-6至-2天静脉输注磷酸氟达拉滨30分钟,第-3至-2天静脉输注美法仑,第-3天开始口服环孢素每日两次。第-3天开始口服西罗莫司每日两次,将给予配型相合无关供者的患者
【主题与分类】
主题标签:Chronic Myelomonocytic Leukemia-2、High Grade Malignant Neoplasm、Myelodysplastic Syndrome、Myeloid Neoplasm、Recurrent Acute Myeloid Leukemia、Refractory Acute Myeloid Leukemia。本站分类:肿瘤/白血病。
【获取与许可】
源站页面:https://clinicaltrials.gov/study/NCT02756572
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取
源站:https://clinicaltrials.gov/study/NCT02756572
标准获取流程:
- 访问源站链接,注册/登录账号;
- 进入数据集详情页,按页面指引申请权限或直接下载;
- 部分平台提供 SDK,例如:
- OpenDataLab:
pip install openxlab后openxlab.dataset.get(...) - ModelScope:
pip install modelscope后modelscope download - 天池: 登录后页面提供直链下载
以源站「数据下载/使用文档」页面为准。
- OpenDataLab:
数据说明
Conditions: Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia. OUTLINE: RE-INDUCTION CHEMOTHERAPY: Patients receive filgrastim subcutaneously (SC) on days 0-5, mitoxantrone hydrochloride intravenously (IV) over 60 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and cytarabine IV over 2 hours on days 1-5. CONDITIONING REGIMEN: Beginning 14-60 days after re-induction chemotherapy, patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2, melphalan IV on days -3 to -2, cyclosporine orally (PO) twice daily (BID) starting on day -3. Sirolimus PO BID starting on day -3 will be given to patients who have matched unrelated donors or mismatched unrelated donors. Patients >55 years or with significant co-morbidities will only receive melphalan IV on day -2 and will also receive total body irradiation (TBI) on day -1 or day 0. EARLY TRANSPLANT: Patients undergo allogeneic HCT after conditioning regimen on day 0. GVHD PROPHYLAXIS: Patients with matched donors will receive mycophenolate mofetil PO three times daily (TID) on days 0-30, then twice a day (BID) until day 40; and cyclosporine PO BID on days -3 to 96, with a taper until day 150. Patients with matched unrelated donors also receive sirolimus PO BID on days -3 to 150, with a taper until day 180. Patients with mismatched unrelated donors will receive mycophenolate mofetil PO TID on days 0-30, then BID until day 100, with a taper until day 150; cyclosporine PO BID on days -3 to 150, then taper until day 180; and sirolimus BID PO days -3 to 180, then a taper until day 365. After completion of study treatment, patients are followed up periodically.
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




